# US 2013/0281544 A1 · Hepatoprotectant activity of garcinol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0281544 A1
- Document ID: US20130281544A1
- Status: Published application
- Kind: A1
- Application number: 13/885,781
- Filed: 2011-12-29
- Published: 2013-10-24
- Earliest claimed: 2010-12-30
- Inventors: Muhammed Majeed; Sarang Bani
- Web page: https://patentgrep.com/patent/US20130281544A1

## CPC

- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 36/38: Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention discloses the hepatoprotective potential of garcinol.

## Claims

### Claim 1

A method of mammalian hepatocyte protection, said method comprising step of bringing into contact mammalian hepatocytes with an effective concentration of garcinol.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the effective concentration of garcinol is from about 0.78 μg/ml to about 6.25 μg/ml.

### Claim 3

A method of reducing increased levels of cytokine expression in mammalian models of liver damage (hepatotoxicity), said method comprising step of administering an effective amount of garcinol to said models.

### Claim 4 (depends on 3)

The method according to claim 3, where in the cytokine is Transforming Growth Factor G-β1 (TGF-β1).

### Claim 5 (depends on 3)

The method according to claim 3, wherein the cytokine is Tumor Necrosis Factor-α.

### Claim 6 (depends on 3)

The method according to claim 3, wherein the cytokine is Interleukin-2 (IL-2).

### Claim 7 (depends on 3)

The method according to claim 3, wherein the cytokine is Interleukin-4 (IL-4).

### Claim 8 (depends on 3)

The method according to claim 3, wherein the cytokine is Interleukin-12 (IL-12).

### Claim 9 (depends on 3)

The method according to claim 3, wherein hepatotoxicity is caused by toxin.

### Claim 10 (depends on 3)

The method according to claim 3, wherein hepatotoxicity is caused by drugs.

### Claim 11 (depends on 3)

The method according to claim 3, wherein hepatotoxicity is caused by ethyl alcohol.

### Claim 12

A method of reducing increased levels of adhesion molecule expression in mammalian models of liver damage (hepatotoxicity), said method comprising step of administering an effective amount of garcinol to said models.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the adhesion molecule is intracellular Adhesion Molecule-1 (ICAM-1 or CD 52).

### Claim 14 (depends on 12)

The method according to claim 12, wherein hepatotoxicity is caused by toxin.

### Claim 15 (depends on 12)

The method according to claim 12, wherein hepatotoxicity is caused by drugs.

### Claim 16

A method of reducing elevated levels of liver enzymes and/or bile pigments in mammalian models of liver damage (hepatotoxicity), said method comprising step of administering an effective amount of garcinol to said models.

### Claim 17 (depends on 16)

The method according to claim 16, wherein hepatotoxicity is caused by toxin.

### Claim 18 (depends on 16)

The method according to claim 16, wherein hepatotoxicity is caused by drugs.

### Claim 19 (depends on 16)

The method according to claim 16, wherein hepatotoxicity is caused by ethyl alcohol.

### Claim 20 (depends on 16)

The method according to claim 16, wherein the liver enzyme is selected from a group comprising Alanine Transaminase, Aspartate aminotransferase and Alkaline Phosphatase.

### Claim 21 (depends on 16)

The method according to claim 16, wherein the bile pigment is bilirubin.

### Claim 22

A method of providing hepatoprotection, said method comprising step of administering a therapeutically effective amount of garcinol to a subject in need thereof.
